From Attacking Parkinson’s Via Gaucher Link, LTI Ready for Its Series A:

Kees Been, CEO of Lysosomal Therapeutics (LTI)
Kees Been, CEO of Lysosomal Therapeutics (LTI)

Kees Been, CEO of Lysosomal Therapeutics (LTI)